Collaboration between the transplant community, industry, and regulatory agencies develops biomarker aimed to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients. CARY, N.C. , June 22, 2020 /PRNewswire/ -- Critical Path
Company Release no. 13/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 February 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Today, Veloxis Pharmaceuticals A/S' Extraordinary General Meeting passed the
Company Release no. 12/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 29 January 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S As announced in company release
Selskabsmeddelelse nr. 12/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 29. januar 2020 Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Som meddelt ved
Company Announcement no. 11/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 24 January 2020 Notice to Convene Extraordinary General Meeting Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no.
Company Release no. 10/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S' Shares from Nasdaq Copenhagen Following company release no.
Selskabsmeddelelse nr. 10/2020 Til: NASDAQ Copenhagen A/S København, Danmark, fredag den 24. januar 2020 Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Med henvisning til
Company Release no. 9/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S Pursuant to Sections 70-72 of the Danish Companies Act, Asahi Kasei
Selskabsmeddelelse nr. 9/2020 Til: NASDAQ Copenhagen A/S København, Danmark, fredag den 24. januar 2020 Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceuticals A/S Asahi Kasei Pharma Denmark A/S har fremsendt meddelelse om tvangsindløsning til aktionærerne i Veloxis
Company Release no. 8/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Veloxis Pharmaceuticals A/S: Major Shareholder Notifications Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") hereby announces that it has received
Company Release no. 7/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Thursday 23 January 2020 Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer On 17
Selskabsmeddelelse nr. 7/2020 Til: NASDAQ Copenhagen A/S København, Danmark, torsdag den 23. januar 2020 Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud
Company Release no. 6/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 January 2020 Asahi Kasei Pharma Denmark A/S Announces the Final Result of the Voluntary Public Tender Offer Asahi Kasei Pharma Denmark A/S, which on 15 January 2020 announced
Selskabsmeddelelse nr. 6/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 17. januar 2020 Asahi Kasei Pharma Denmark A/S meddeler det endelige resultat det frivillige offentlige købstilbud Asahi Kasei Pharma Denmark A/S, som den 15. januar 2020 offentliggjorde det foreløbige resultat af det
Company Release no. 5/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 January 2020 Veloxis Pharmaceuticals: Reporting of Managers' and Closely Associated Persons' Transactions in Veloxis-Shares and Financial Instruments Linked Hereto Today, Veloxis
Selskabsmeddelelse nr. 5/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 15. januar 2020 Veloxis Pharmaceuticals: Offentliggørelse af ledende medarbejderes og personer, der er nært knyttet til ledende medarbejderes transaktioner med Veloxis-aktier og finansielle instrumenter forbundet hermed
Company Release no. 4/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 January 2020 Veloxis Pharmaceuticals: Major Shareholder Notifications Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") hereby announces that it has received major
Company Release no. 3/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 January 2020 Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark Announces the Preliminary Result and Completion of its Public Tender Offer for the Shares and Warrants in
Selskabsmeddelelse nr. 3/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 15. januar 2020 Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark offentliggør det foreløbige resultat af samt afslutningen på dets offentlige købstilbud på aktier og warrants i Veloxis Pharmaceuticals Asahi Kasei
Company Release no. 2/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 12 January 2020 Veloxis Pharmaceuticals: Reminder of Approaching Deadline for the Acceptance of the Public Tender Offer by Asahi Kasei Pharma Denmark Please refer to the
Company Release no. 1/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 09 January 2020 Veloxis Pharmaceuticals: Competition approvals obtained for the public tender offer by Asahi Kasei Pharma Denmark for the shares and warrants in Veloxis
